×
Indication
×
BLINCYTO® (blinatumomab) is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.
This site is intended for US health care professionals only.
Indication
BLINCYTO® (blinatumomab) for injection 35 mcg single-use vial
ABOUT BLINCYTO® (blinatumomab)
HOW BLINCYTO® WORKS*
BLINCYTO® (blinatumomab) Is a Bispecific CD3-CD19 T-cell Engager

TARGET

BLINCYTO® binds to CD19 expressed on the surface of cells of
B-lineage origin and CD3 expressed on the surface of T cells, forming a synapse.1

BLINCYTO® (blinatumomab) Engages T Cells

ENGAGE

Once the synapse is formed, BLINCYTO® leads to upregulation of cell adhesion molecules and the production of cytolytic proteins.1

BLINCYTO® (blinatumomab) Activates Endogenous T Cells

ACTIVATE

The release of inflammatory cytokines, and proliferation of T cells, results in redirected lysis of CD19+ cells.1

The First and Only FDA-Approved Bispecific CD19-Directed CD3 T-cell Engager1,2
CD19 EXPRESSION
CD19 IS AN IDEAL TARGET FOR B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) THERAPY3,4
Surface Antigen Expression Throughout the B-Cell Life Cycle5
Surface Antigen Expression Throughout the B-Cell Life Cycle
  • CD19 is present on both healthy and malignant cells of B-lineage origin, and is critically important for B-cell function and tumor survival8-10

CD19 is ubiquitously expressed in B-precursor ALL, with expression levels of ≥ 95% on B-lineage cells6,7
Back to Top
References:
  1. BLINCYTO® (blinatumomab) Prescribing Information, Amgen.
  2. Data on file, Amgen; [FDA letter]; 2014.
  3. Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol. 2013;5:5-11.
  4. Nagorsen D, Bargou R, Ruttinger D, et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma. 2009;50:886-891.
  5. Longo DL. Malignancies of lymphoid cells. In: Longo DL, Fauci AS, Kasper DL, et al, eds. Harrison’s Principles of Internal Medicine, 18th ed. New York, NY: McGraw-Hill; 2012:chap 110. http://accessmedicine.mhmedical.com/content.aspx?bookid=331&Sectionid=40726848. Accessed December 12, 2014.
  6. Hoelzer D. Novel antibody-based therapies for acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2011;2011:243-249.
  7. Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52:1098-1107.
  8. Otero DC, Omori SA, Rickert RC. CD19-dependent activation of Akt kinase in B-lymphocytes. J Biol Chem. 2001;276:1474-1478.
  9. Aiba Y, Kameyama M, Yamazaki T, Tedder TF, Kurosaki T. Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood. 2008;111:1497-1503.
  10. Pauls SD, Lafarge ST, Landego I, Zhang T, Marshall AJ. The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front Immunol. 2012;3:224.